Everest Medicines has signed a memorandum of understanding (MoU) for a collaboration with China Resources Pharmaceutical Group (CR Pharma) to set up an independent company focused on messenger ribonucleic acid (mRNA) vaccine development.
Named ‘the mRNA’, the new company will advance its possibly best-in-class mRNA vaccine candidates through regulatory pathways in China and into marketing.
Go deeper with GlobalData
CR Pharma plans to make a strategic equity investment for the mRNA technology platform of Everest.
In September last year, Everest had signed a strategic collaboration with Providence Therapeutics to develop mRNA vaccines and therapies.
Under this deal, Everest holds the rights to mRNA vaccine candidates of Providence, including PTX-COVID19-B, in Greater China, Brunei, Cambodia, Indonesia and Malaysia among others.
See Also:
Under the latest MoU, the mRNA will become a fully functional, independent company and assume the rights under the agreement with Providence, including the full technology platform, and mRNA manufacturing infrastructure of Everest.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataEverest will become the mRNA’s largest and controlling shareholder.
Furthermore, the mRNA will expedite the late-stage development and registration of PTX-COVID19-B and advance the development of a second-generation Covid-19 vaccine and two partnership projects with Providence for new mRNA vaccines.
The mRNA will also progress to build global GMP manufacturing site of Everest in Jiashan, Zhejiang Province, which is slated to become operational by the end of this year.
On concluding the construction, the first phase of production will be intended for PTX-COVID19-B vaccine, with a projected capacity of 700-800 million doses annually.
Everest Medicines chairman Wei Fu said: “We are pleased with Everest’s ability to continually grow the business, as well as its industry leadership and reputation, by executing strategic collaborations and partnerships with key stakeholders like CR Pharma, which provide valuable expertise and resources to critical ventures such as this.
“This potential collaboration propels forward the development of Everest’s mRNA vaccines, and shows our commitment to bring highly sought-after mRNA vaccines to China.”
